PMPRB report shows higher-cost medicines driving drug costs 

ShaziaMedicine

Ottawa –  The Patented Medicine Prices Review Board has published its latest report, Private Drug Plans in Canada: Expenditure Report, 2018–2023. This report provides insight into the factors driving growth in prescription drug costs for private drug plans in 2023, as well as a retrospective review of trends in private drug plan costs and utilization since 2018. As key stakeholders in the …

PMPRB report reviews new drugs, impact on future spending in Canada

eAwazMedicine

Ottawa – The latest edition of Meds Pipeline Monitor, from the Patented Medicine Prices Review Board, provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may significantly impact clinical practice or drug spending in the coming years. There were over 12,000 drugs in the pipeline in 2023, increasing by an average of 19% per …